Innovative trifocal (quadrifocal) presbyopia-correcting IOLs: 1-year outcomes from an international multicenter study.

ABSTRACT:

Purpose

To evaluate visual acuity (VA) and safety of the new AcrySof IQ PanOptix presbyopia-correcting IOL at 12 months postimplantation.

Setting

Seventeen sites in Europe, Australia, and South America.

Design

Prospective, single-arm, nonmasked, nonrandomized study.

Methods

Of 167 patients enrolled, 149 received study IOLs in both eyes; 145 completed the study. Binocular uncorrected distance VA (UDVA; 4 m), monocular corrected distance VA (CDVA), binocular distance-corrected intermediate VA (DCIVA; 60 cm and 80 cm), binocular uncorrected near VA (UNVA; 40 cm), and binocular defocus curves were evaluated. Safety was assessed by monitoring adverse events (AEs).

Results

Of 149 patients, 92 patients (62%) were women and 139 patients (93%) were white; mean ±

SUBMITTER: Kohnen T 

PROVIDER: S-EPMC7688079 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature